Deckers CEO: Company culture is what counts
In a globalized world, vision and culture are the keys to creating and marketing successful new products. That’s the message Deckers Outdoor Corp. CEO Angel Martinez brought to about 250 Central Coast business leaders at the Feb. 2 Corporate Leaders Breakfast at California Lutheran University. “Our mission is to find niche brands and turn them Read More →
Read More →Inphi taps new CEO after profits fall 93%
Inphi Corp., the Santa Clara-based chip firm with a large engineering force in Thousand Oaks, ousted its CEO on Feb. 1 as it announced that profits plummeted by 93 percent in 2011. Inphi designs chips aimed at packing more memory into Internet servers and increasing bandwidth in the Internet backbone. The company announced that Ford Read More →
Read More →PCBC reports $70.5M in 2011 profits
[wikichart align=”center” ticker=”PCBC” showannotations=”true” livequote=”true” rollingdate=”6 months” width=”390″ height=”245″] Pacific Capital Bancorp, the largest bank based in the region, earned $70.5 million in 2011, its first full calendar year under the ownership of a Texas-based private equity group. The parent company of Santa Barbara Bank & Trust saw its fourth-quarter profits drop 39.8 percent to Read More →
Read More →
Under scrutiny, First California targets South Coast
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Ceres to debut at $21 to $23 per share
Thousand Oaks-based energy crop developer Ceres has plans to make its debut on the Nasdaq on Feb. 8 under the symbol CERE and raise $132 million. Shares in the company, which uses genetic marking technology to speed the development of non-food energy crops such as drought-resistant switchgrass, are expected hit the markets at between $21 Read More →
Read More →Amgen Q4 earnings drop 8.5%
[wikichart align=”right” ticker=”NASDAQ:AMGN” showannotations=”true” livequote=”true” startdate=”26-07-2011″ enddate=”26-01-2012″ width=”300″ height=”245″] Biotech giant Amgen, which said earlier on Thursday that it would pay $1.2 billion for leukemia drugmaker Micromet, reported fourth-quarter earnings that missed analyst expectations. The Thousand Oaks-based company said fourth-quarter profits fell 8.5 percent to $934 million, or $1.08 per share, on lower sales of Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
